Bone Metastases in NEN Patients - Frequency, Clinical, Therapeutic and Prognostic Relevance Abstract #1271

Introduction: Up to 73% of patients with neuroendocrine neoplasms (NEN) present with distant metastases at diagnosis. Advanced stage negatively correlates with prognosis. Bone metastases (BM) are usually reported in less than 10% of patients. Improved imaging results in more frequent detection but information in general is very limited.
Aim(s): Presentation of a single-center experience on frequency, clinical and therapeutic relevance of BM.
Materials and methods: All patients treated in the ENETs center in Marburg, Germany, between 2000 and June 2015 listed in our NEN-database were evaluated for inclusion. Out of 709 patients 414 had distant metastases (58.4 %) including 109 with BM (15.4%). 84 patients qualified for inclusion in our study.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: MD Michael Scharf

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2733 Pancreatic Metastases Originating from Intestinal Neuroendocrine Tumours
Introduction: Pancreatic metastases are rare, accounting for 1 to 2% of pancreatic tumours. Data on pancreatic metastases of intestinal NETs are lacking.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: MD Anja Rinke
#2891 Bone Metastases and Skeletal Related Events in Patients with Neuroendocrine Neoplasms (NEN): The Role of Zoledronic Acid
Introduction: The incidence of bone metastases (BM) in patients with NENs is 12-25%, and skeletal related events (SREs) occur in up to 21% of affected cases. Data about the efficacy of bisphosphonates in NEN patients (pts) with BM are limited.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - others, not specified
Presenting Author: Dr Eleni Armeni
#2763 Incidence and Outcome of Brain Metastasis in Patients Diagnosed with Neuroendocrine Neoplasm
Introduction: Brain metastases are rarely reported in patients with neuroendocrine carcinoma of non-lung origin and neuroendocrine tumors (NETs) of the gastroenteropancreatic or bronchopulmonary system.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Pathology - grading, staging
Presenting Author: Dr Arooj Fatima
Authors: Fatima A, Zaidi S S A, ...
#2903 Bone Metastases (BM) in Neuroendocrine Tumors (NET): Imaging Characteristics and Clinical Implications. A Single-Institution Experience
Introduction: The incidence of BM in NET is underestimated and there is no consensus on clinical features, diagnostic techniques, and treatment options.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Imaging and Interventions (radiology, endoscopy)
Presenting Author: Valeria Smiroldo
Authors: Smiroldo V, Lania A, Pedicini V, Pepe G, ...
#2805 Small Bowel Neuroendocrine Tumor Metastases: Comparison of Contrast-Enhanced Computed Tomography and 68Ga-DOTATATE PET/CT
Introduction: Most gastrointestinal neuroendocrine tumors (GI-NETs) involve the small intestine (38%) and about 50% of patients present with regional or distant metastases at time of diagnosis [2]. 68Ga-DOTATATE PET/CT provides improved sensitivity and specificity compared to traditional nuclear medicine techniques [4]. However, there is relatively less data comparing performance of 68Ga-DOTATATE PET/CT with contrast-enhanced CT (CECT).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Imaging and Interventions (radiology, endoscopy)
Presenting Author: Hannah Monahan